Psychotropic drug use in community-dwelling people with young-onset dementia: two-year course and determinants

References

• Aalten, P., de Vugt, M. E., Jaspers, N., Jolles, J., & Verhey, F. R. (2005). The course of neuropsychiatric symptoms in dementia. Part I: Findings from the two-year longitudinal Maasbed study. International Journal of Geriatric Psychiatry, 20(6), 523–530. doi:10.1002/gps.1316
   PubMed Web of Science ®Google Scholar
• Aalten, P., Verhey, F. R. J., Boziki, M., Brugnolo, A., Bullock, R., Byrne, E. J., … Robert, P. H. (2008). Consistency of neuropsychiatric syndromes across dementias: Results from the European Alzheimer Disease Consortium. Dementia and Geriatric Cognitive Disorders, 25(1), 1–8. doi:10.1159/000111082
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders-Text revision: DSM-IV-TR. Arlington: American Psychiatric Association.
   Google Scholar
• Appelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., … Koopmans, R. T. C. M. (2017). The determinants of quality of life of nursing home residents with young-onset dementia and the differences between dementia subtypes. Dementia and Geriatric Cognitive Disorders, 43(5–6), 320–329. doi:10.1159/000477087
   PubMed Web of Science ®Google Scholar
• Appelhof, B., Bakker, C., Van Duinen-van Den, I. J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., … Koopmans, R. (2019). Differences in neuropsychiatric symptoms between nursing home residents with young-onset dementia and late-onset dementia. Aging & Mental Health, 23(5), 581–586. doi:10.1080/13607863.2018.1428935
   PubMed Web of Science ®Google Scholar
• Arai, A., Matsumoto, T., Ikeda, M., & Arai, Y. (2007). Do family caregivers perceive more difficulty when they look after patients with early onset dementia compared to those with late onset dementia? [Research Support, Non-U.S. Gov't]. Int J Geriatr Psychiatry, 22(12), 1255–1261. doi:10.1002/gps.1935
   PubMed Web of Science ®Google Scholar
• Azermai, M., Vander Stichele, R. R., Van Bortel, L. M., & Elseviers, M. M. (2014). Barriers to antipsychotic discontinuation in nursing homes: An exploratory study. Aging & Mental Health, 18(3), 346–353. doi:10.1080/13607863.2013.832732
   PubMed Web of Science ®Google Scholar
• Bakker, C., de Vugt, M. E., van Vliet, D., Verhey, F. R., Pijnenburg, Y. A., Vernooij-Dassen, M. J., & Koopmans, R. T. (2013a). Predictors of the time to institutionalization in young- versus late-onset dementia: Results from the Needs in Young Onset Dementia (NeedYD) study. Journal of the American Medical Directors Association, 14(4), 248–253. doi:10.1016/j.jamda.2012.09.011
   PubMed Web of Science ®Google Scholar
• Bakker, C., de Vugt, M. E., van Vliet, D., Verhey, F. R., Pijnenburg, Y. A., Vernooij-Dassen, M. J., & Koopmans, R. T. (2013b). The use of formal and informal care in early onset dementia: Results from the NeedYD study. [Research Support, Non-U.S. Gov’t]. The American Journal of Geriatric Psychiatry, 21(1), 37–45. doi:10.1016/j.jagp.2012.10.004
   PubMed Web of Science ®Google Scholar
• Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., … Burns, A. (2011). Sertraline or mirtazapine for depression in dementia (HTA-SADD): A randomised, multicentre, double-blind, placebo-controlled trial. The Lancet, 378(9789), 403–411. doi:10.1016/S0140-6736(11)60830-1
   PubMed Web of Science ®Google Scholar
• Belvederi Murri, M., Guaglianone, A., Bugliani, M., Calcagno, P., Respino, M., Serafini, G., … Amore, M. (2015). Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis. [journal article]. Drugs in R&D, 15(1), 45–62. doi:10.1007/s40268-014-0078-0
   PubMed Web of Science ®Google Scholar
• Boots, L. M., de Vugt, M. E., Kempen, G. I., & Verhey, F. R. (2018). Effectiveness of a blended care self-management program for caregivers of people with early-stage dementia (partner in balance): Randomized controlled trial. Journal of Medical Internet Research, 20(7), e10017. doi:10.2196/10017
   PubMed Web of Science ®Google Scholar
• Borsje, P., Lucassen, P., Wetzels, R. B., Pot, A. M., & Koopmans, R. (2018). Neuropsychiatric symptoms and psychotropic drug use in patients with dementia in general practices. Family Practice, 35(1), 22–28. doi:10.1093/fampra/cmx061
   PubMed Web of Science ®Google Scholar
• Boucherie, Q., Gentile, G., Chalancon, C., Sciortino, V., Blin, O., Micallef, J., & Bonin-Guillaume, S. (2017). Long-term use of antipsychotics in community-dwelling dementia patients: Prevalence and profile accounting for unobservable time bias because of hospitalization. International Clinical Psychopharmacology, 32(1), 13–19. doi:10.1097/YIC.0000000000000150
   PubMed Web of Science ®Google Scholar
• Brodaty, H., Ames, D., Snowdon, J., Woodward, M., Kirwan, J., Clarnette, R., … Greenspan, A. (2005). Risperidone for psychosis of Alzheimer's disease and mixed dementia: Results of a double-blind, placebo-controlled trial. International Journal of Geriatric Psychiatry, 20(12), 1153–1157. doi:10.1002/gps.1409
   PubMed Web of Science ®Google Scholar
• Calvo-Perxas, L., de Eugenio, R. M., Marquez-Daniel, F., Martinez, R., Serena, J., Turbau, J, … Registry of Dementias of Girona, S. (2012). Profile and variables related to antipsychotic consumption according to dementia subtypes. International Psychogeriatrics, 24(6), 940–947. doi:10.1017/S1041610212000026
   PubMed Web of Science ®Google Scholar
• Campbell, N., Ayub, A., Boustani, M. A., Fox, C., Farlow, M., Maidment, I., & Howards, R. (2008). Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis. Clinical Interventions in Aging, 3(4), 719–728.
   PubMed Web of Science ®Google Scholar
• Cornege-Blokland, E., Kleijer, B. C., Hertogh, C. M., & van Marum, R. J. (2012). Reasons to prescribe antipsychotics for the behavioral symptoms of dementia: A survey in Dutch nursing homes among physicians, nurses, and family caregivers. Journal of American Medical Directors Association, 13(1), 80.e1–80.e6. doi:10.1016/j.jamda.2010.10.004
   Web of Science ®Google Scholar
• Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994). The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology, 44(12), 2308–2314. doi:10.1212/WNL.44.12.2308
   PubMed Web of Science ®Google Scholar
• Draper, B., & Withall, A. (2016). Young onset dementia. Internal Medicine Journal, 46(7), 779–786. doi:10.1111/imj.13099
   PubMed Web of Science ®Google Scholar
• Dudas, R., Malouf, R., McCleery, J., & Dening, T. (2018). Antidepressants for treating depression in dementia. The Cochrane Database of Systematic Reviews, 8, CD003944. doi:10.1002/14651858.CD003944
   PubMedGoogle Scholar
• Erkinjutti T. (1994). Clinical criteria for vascular dementia: the NINDS-AIREN criteria. Dementia, 5, 189–92.
   PubMedGoogle Scholar
• Foley, T., Boyle, S., Jennings, A., & Smithson, W. H. (2017). We’re certainly not in our comfort zone”: A qualitative study of GPs’ dementia-care educational needs. BMC Family Practice, 18(1), 66. doi:10.1186/s12875-017-0639-8
   PubMedGoogle Scholar
• Gerritsen, A. A., de Jonghe-Rouleau, A. P., & Stienstra-Liem, L. H. (2004). Neuroleptic malignant syndrome in users of risperidone. Nederlands Tijdschrift voor Geneeskunde, 148(37), 1801–1804.
   PubMedGoogle Scholar
• Gerritsen, A. A. J., Bakker, C., Verhey, F. R. J., Bor, H., Pijnenburg, Y. A. L., de Vugt, M. E., & Koopmans, R. (2018). The progression of dementia and cognitive decline in a Dutch 2-year cohort study of people with young-onset dementia. Journal of Alzheimer’s Disease, 63(1), 343–351. doi:10.3233/JAD-170859
   PubMed Web of Science ®Google Scholar
• Kales, H. C., Kim, H. M., Zivin, K., Valenstein, M., Seyfried, L. S., Chiang, C., … Blow, F. C. (2012). Risk of mortality among individual antipsychotics in patients with dementia. American Journal of Psychiatry, 169(1), 71–79. doi:10.1176/appi.ajp.2011.11030347
   PubMed Web of Science ®Google Scholar
• Kat, M. G., de Jonghe, J. F., Aalten, P., Kalisvaart, C. J., Droes, R. M., & Verhey, F. R. (2002). Neuropsychiatric symptoms of dementia: Psychometric aspects of the Dutch Neuropsychiatric Inventory (NPI). Tijdschrift voor Gerontologie en Geriatrie, 33(4), 150–155.
   PubMedGoogle Scholar
• Katz, I. R., Jeste, D. V., Mintzer, J. E., Clyde, C., Napolitano, J., & Brecher, M. (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Risperidone Study Group. The Journal of Clinical Psychiatry, 60(2), 107–115. doi:10.4088/JCP.v60n0207
   PubMed Web of Science ®Google Scholar
• Kester, R., Unutzer, J., Hogan, D., & Huang, H. (2017). Antipsychotic prescribing patterns in a Medicare Advantage population of older individuals with dementia. Journal of Mental Health, 26(2), 167–171. doi:10.1080/09638237.2016.1244720
   PubMed Web of Science ®Google Scholar
• Koopmans, R. T., Reinders, R., van Vliet, D., Verhey, F. R., de Vugt, M. E., Bor, H., & Bakker, C. (2014). Prevalence and correlates of psychotropic drug use in community-dwelling people with young-onset dementia: The NeedYD-study. International Psychogeriatrics, 26(12), 1983–1989. doi:10.1017/S1041610213002330
   PubMed Web of Science ®Google Scholar
• Lavretsky, H., & Sultzer, D. (1998). A structured trial of risperidone for the treatment of agitation in dementia. American Journal of Geriatric Psychiatry, 6(2), 127–135. doi:10.1097/00019442-199821000-00006
   PubMed Web of Science ®Google Scholar
• Lim, L., Zhang, A., Lim, L., Choong, T. M., Silva, E., Ng, A., & Kandiah, N. (2018). High caregiver burden in young onset dementia: What factors need attention? Journal of Alzheimer’s Disease, 61(2), 537–543. doi:10.3233/JAD-170409
   PubMed Web of Science ®Google Scholar
• Lornstad, M. T., Aaroen, M., Bergh, S., Benth, J. S., & Helvik, A. S. (2019). Prevalence and persistent use of psychotropic drugs in older adults receiving domiciliary care at baseline. BMC Geriatrics, 19(1), 119. doi:10.1186/s12877-019-1126-y
   PubMedGoogle Scholar
• Masopust, J., Protopopova, D., Valis, M., Pavelek, Z., & Klimova, B. (2018). Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: A review. Neuropsychiatric Disease and Treatment, 14, 1211–1220. doi:10.2147/NDT.S163842
   PubMed Web of Science ®Google Scholar
• Massot Mesquida, M., Tristany Casas, M., Franzi Siso, A., Garcia Munoz, I., Hernandez Vian, O., & Toran Monserrat, P. (2019). Consensus and evidence-based medication review to optimize and potentially reduce psychotropic drug prescription in institutionalized dementia patients. BMC Geriatrics, 19(1), 7. doi:10.1186/s12877-018-1015-9
   PubMedGoogle Scholar
• Mesulam, M. M., Grossman, M., Hillis, A., Kertesz, A., & Weintraub, S. (2003). The core and halo of primary progressive aphasia and semantic dementia. Ann Neurol, 54(Suppl 5), S11–S14. doi:10.1002/ana.10569
   PubMed Web of Science ®Google Scholar
• McKeith, I. G. (2006). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis, 9(3 Suppl), 417–423. doi:10.3233/JAD-2006-9S347
   PubMedGoogle Scholar
• McKhann G., Drachman D., Folstein M., Katzman R., Price D., & Stadlan E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939–44. doi:10.1212/WNL.34.7.939
   PubMed Web of Science ®Google Scholar
• Mengelers, A., Bleijlevens, M. H. C., Verbeek, H., Capezuti, E., Tan, F. E. S., & Hamers, J. P. H. (2018). Professional and family caregivers’ attitudes towards involuntary treatment in community-dwelling people with dementia. Journal of Advanced Nursing, 75(1), 96–107. doi:10.1111/jan.13839
   PubMed Web of Science ®Google Scholar
• Moll van Charante, E., Perry, M., Vernooij-Dassen, M., Boswijk, D. F. R., Stoffels, J., Achthoven, L., & Luning-Koster, M. N. (2012). NHG-Standaard Dementie (derde herziening). Huisarts en Wetenschap, 55(7), 306–317.
   Google Scholar
• Neary D. et al. (1998). Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology, 51, 1546–54. doi:10.1212/WNL.51.6.1546
   PubMed Web of Science ®Google Scholar
• Nielsen, R. E., Lolk, A., Rodrigo-Domingo, M., Valentin, J. B., & Andersen, K. (2017). Antipsychotic treatment effects on cardiovascular, cancer, infection, and intentional self-harm as cause of death in patients with Alzheimer’s dementia. European Psychiatry, 42, 14–23. doi:10.1016/j.eurpsy.2016.11.013
   PubMed Web of Science ®Google Scholar
• Nordic Council on Medicines. (1990). The anatomical therapeutic chemical classification system with defined daily doses (ATC/DDD). Oslo, Norway: The WHO Collaborating Centre.
   Google Scholar
• Rabinowitz, J., Katz, I. R., De Deyn, P. P., Brodaty, H., Greenspan, A., & Davidson, M. (2004). Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. The Journal of Clinical Psychiatry, 65(10), 1329–1334. doi:10.4088/JCP.v65n1006
   PubMed Web of Science ®Google Scholar
• Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine, 360(3), 225–235. doi:10.1056/NEJMoa0806994
   PubMed Web of Science ®Google Scholar
• Reisberg, B., Ferris, S. H., de Leon, M. J., & Crook, T. (1982). The Global Deterioration Scale for assessment of primary degenerative dementia. [Research Support, U.S. Gov’t, P.H.S.]. American Journal of Psychiatry, 139(9), 1136–1139.
   PubMed Web of Science ®Google Scholar
• Rochon, P. A., Normand, S. L., Gomes, T., Gill, S. S., Anderson, G. M., Melo, M., … Gurwitz, J. H. (2008). Antipsychotic therapy and short-term serious events in older adults with dementia. Archives of Internal Medicine, 168(10), 1090–1096. doi:10.1001/archinte.168.10.1090
   PubMedGoogle Scholar
• Rosness, T. A., Barca, M. L., & Engedal, K. (2010). Occurrence of depression and its correlates in early onset dementia patients. International Journal of Geriatric Psychiatry, 25(7), 704–711. doi:10.1002/gps.2411
   PubMed Web of Science ®Google Scholar
• Schneider, L. S., Katz, I. R., Park, S., Napolitano, J., Martinez, R. A., & Azen, S. P. (2003). Psychosis of Alzheimer disease: Validity of the construct and response to risperidone. The American Journal of Geriatric Psychiatry, 11(4), 414–425. doi:10.1097/00019442-200307000-00004
   PubMed Web of Science ®Google Scholar
• Tampi, R. R., & Tampi, D. J. (2014). Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: A systematic review of randomized controlled trials. American Journal of Alzheimer’s Disease & Other Dementias, 29(7), 565–574. doi:10.1177/1533317514524813
   PubMed Web of Science ®Google Scholar
• Tanaka, H., Hashimoto, M., Fukuhara, R., Ishikawa, T., Yatabe, Y., Kaneda, K., … Ikeda, M. (2015). Relationship between dementia severity and behavioural and psychological symptoms in early-onset Alzheimer's disease. Psychogeriatrics, 15(4), 242–247. doi:10.1111/psyg.12108
   PubMed Web of Science ®Google Scholar
• Tariot, P. N., Schneider, L., Katz, I. R., Mintzer, J. E., Street, J., Copenhaver, M., & Williams-Hughes, C. (2006). Quetiapine treatment of psychosis associated with dementia: A double-blind, randomized, placebo-controlled clinical trial. The American Journal of Geriatric Psychiatry, 14(9), 767–776. doi:10.1097/01.JGP.0000196628.12010.35
   PubMed Web of Science ®Google Scholar
• Tormalehto, S., Martikainen, J., Bell, J. S., Hallikainen, I., & Koivisto, A. M. (2017). Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer’s disease over a three-year period: Kuopio ALSOVA study. International Psychogeriatrics, 29(10), 1723–1733. doi:10.1017/S1041610217001090
   PubMed Web of Science ®Google Scholar
• van der Spek, K., Gerritsen, D. L., Smalbrugge, M., Nelissen-Vrancken, M. H. J. M. G., Wetzels, R. B., Smeets, C. H. W., … Koopmans, R. T. C. M. (2016). Only 10% of the psychotropic drug use for neuropsychiatric symptoms in patients with dementia is fully appropriate. The PROPER I-study. International Psychogeriatrics, 28(10), 1589–1595. doi:10.1017/S104161021600082X
   PubMed Web of Science ®Google Scholar
• van der Spek, K., Koopmans, R. T. C. M., Smalbrugge, M., Nelissen-Vrancken, M. H. J. M. G., Wetzels, R. B., Smeets, C. H. W., … Gerritsen, D. L. (2018). The effect of biannual medication reviews on the appropriateness of psychotropic drug use for neuropsychiatric symptoms in patients with dementia: A randomised controlled trial. Age and Ageing, 47(3), 430–437. doi:10.1093/ageing/afy001
   PubMed Web of Science ®Google Scholar
• van Vliet, D., Bakker, C., Koopmans, R. T., Vernooij-Dassen, M. J., Verhey, F. R., & de Vugt, M. E. (2010). Research protocol of the NeedYD-study (Needs in Young onset Dementia): A prospective cohort study on the needs and course of early onset dementia. BMC Geriatrics, 10(1), 13. doi:10.1186/1471-2318-10-13
   PubMedGoogle Scholar
• Wetzels, R. B., Zuidema, S. U., de Jonghe, J. F., Verhey, F. R., & Koopmans, R. T. (2011). Prescribing pattern of psychotropic drugs in nursing home residents with dementia. International Psychogeriatrics, 23(8), 1249–1259. doi:10.1017/S1041610211000755
   PubMed Web of Science ®Google Scholar
• Zeger, S. L., & Liang, K. Y. (1986). Longitudinal data analysis for discrete and continuous outcomes. Biometrics, 42(1), 121–130. doi:10.2307/2531248
   PubMed Web of Science ®Google Scholar
• Zuidema, S. U., Smalbrugge, M., Bil, W. E. E., Geelen, R., Kok, R. M., Luyendijk, H. J., … Vreeken, H. L. (2018). Multidisciplinary guideline problem behaviour in dementia. Utrecht: Verenso.
   Google Scholar